Bolt Biotherapeutics
BOLT
39 hedge funds and large institutions have $27M invested in Bolt Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
15% more funds holding
Funds holding: 34 → 39 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less capital inflows, than outflows
Capital inflows: $927K | Capital outflows: $929K
1.13% less ownership
Funds ownership: 64.67% → 63.54% (-1.1%)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$519K |
| 2 |
Renaissance Technologies
New York
|
+$128K |
| 3 |
Tang Capital Management
San Diego,
California
|
+$92.7K |
| 4 |
Two Sigma Securities
New York
|
+$62.5K |
| 5 |
Jane Street
New York
|
+$54.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$384K |
| 2 |
Vivo Capital
Palo Alto,
California
|
-$341K |
| 3 |
Morgan Stanley
New York
|
-$78.2K |
| 4 |
JP Morgan Chase
New York
|
-$73.4K |
| 5 |
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$36.6K |
BOLT Hedge Fund Activity: Q4 2023 in Review
39 of the 6,877 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q4 2023, worth a combined $27M — up 5.9% from $25.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BOLT positions and 1 closed out — a net gain of 6 holders — while 8 added to existing stakes and 11 trimmed.
The largest buyer was Newtyn Management, adding an estimated $519K. The largest seller was Citadel Advisors, cutting an estimated $384K.
- 39 institutional investors held Bolt Biotherapeutics (BOLT) as of Q4 2023, up from 34 in Q3 2023.
- Funds reported $27M of Bolt Biotherapeutics stock for Q4 2023, up 5.9% quarter-over-quarter.
- 7 funds opened new Bolt Biotherapeutics positions in Q4 2023 and 1 closed out, a net change of +6 holders.
- The largest Bolt Biotherapeutics buyer in Q4 2023 was Newtyn Management, an estimated $519K added.
- The largest Bolt Biotherapeutics seller in Q4 2023 was Citadel Advisors, an estimated $384K sold.
Based on aggregated 13F filings for Q4 2023.